Clinical Curative Effects of Pemetrexed Combined with Cisplatin in Treatment for Osteosarcoma Patients with Lung Metastasis

Objective To evaluate the efficacy and safety of pemetrexed combined with cisplatin for metastatic osteosarcoma patients. Methods We collected 18 osteosarcoma patients with lung metastasis with failed first-line chemotherapy, 18 males and 14 females. Median age was 20 years old, and Karnofsky performance status(KPS) score was ≥70. The patients received pemetrexed 500mg/m2 on day 1 and cisplatin 80-100 mg/m2 on day 1-2 by intravenous infusion, 21 days as a cycle. Efficacy and toxicity were evaluated after 2 cycles. Results Totally 18 patients could be evaluated, with 0 case of CR or PR, 1 case of minimal response(MR), 7 cases of stable disease(SD) and 10 cases of progression disease(PD). Disease control rate was 44.4% (8/18). Median progression-free survival and overall survival time were 9.0 weeks (95% CI: 5-13 weeks) and 12.0 months (95%CI: 9-16 months), respectively. The common adverse effects were digestive tract reaction (50.0%), anemia (44.4%) and fatigue (38.9%), which were apparently relieved after symptomatic treatments. Conclusion Pemetrexed combined with cisplatin have certain efficacy for osteosarcoma patients with lung metastasis, with well tolerance and low incidence of adverse reactions.